Yidan Wang

Yidan Wang

Auto-generated profile, based on publicly available information

Yidan Wang

University of Wisconsin–Madison 1 McArdle Laboratory for Cancer Research Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
FLFabao Liu
Fabao Liu
MMMin Ma
Min Ma
AGAng Gao
Ang Gao
FMFengfei Ma
Fengfei Ma
GMGui Ma
Gui Ma
WXWei Xu
Wei Xu

16 November 2022 in Science Advances
Verified
Journal Article
Open access
NCNgai Ting Chan
Ngai Ting Chan
MLMing-Song Lee
Ming-Song Lee
YWYidan Wang
Yidan Wang
JGJacques Galipeau
Jacques Galipeau
WLWan-Ju Li
Wan-Ju Li
WXWei Xu
Wei Xu
Cell fate determination of human mesenchymal stem/stromal cells (hMSCs) is precisely regulated by lineage-specific transcription factors and epigenetic enzymes. We found that CTR9, a key scaffold subunit of polymerase-associated factor complex (PAFc), selectively regulates hMSC differentiation to osteoblasts and chondrocytes, but not to adipocytes. An in vivo ectopic osteogenesis assay confirmed the essentiality of CTR9 in hMSC-derived bone formation. CTR9 counteracts the activity of Enhancer Of Zeste 2 (EZH2), the epigenetic enzyme that deposits H3K27me3, in hMSCs. Accordingly, CTR9 knockdown (KD) hMSCs gain H3K27me3 mark, and the osteogenic differentiation defects of CTR9 KD hMSCs can be partially rescued by treatment with EZH2 inhibitors. Transcriptome analyses identified bone morphology protein–2 (BMP-2) as a downstream effector of CTR9. BMP-2 secretion, membrane anchorage, and the BMP-SMAD pathway were impaired in CTR9 KD MSCs, and the effects were rescued by BMP-2 supplementation. This study uncovers an epigenetic mechanism engaging the CTR9–H3K27me3–BMP-2 axis to regulate the osteochondral lineage differentiation of hMSCs.

29 May 2025 in Cancer Research
Verified
Journal Article
Closed access
EKEui-Jun Kim
Eui-Jun Kim
YWYidan Wang
Yidan Wang
YCYu-Lin Chen
Yu-Lin Chen
MMMin Ma
Min Ma
PLPeng Liu
Peng Liu
WXWei Xu
Wei Xu
The arginine methyltransferase coactivator-associated arginine methyltransferase 1 (CARM1) is amplified/overexpressed in a variety of cancers, including triple-negative breast cancer (TNBC), spurring the interest of developing CARM1 inhibitors (CARM1i). In this study, we discovered that CARM1i treatment leads to elevated CARM1 levels as well as activation of AKT, which could result in long-term treatment resistance in breast cancer cells. CARM1 methylated MAP2K4 at arginine 58 in TNBC, and methylated-MAP2K4 localized to the nucleus and potentiated the proliferation- and metastasis-promoting functions of MAP2K4 via activation of JNK signaling. Inhibition of MAP2K4 by CARM1i led to AKT activation, which was abrogated by treatment with a PI3K inhibitor. Combining CARM1i and PI3K inhibitor elicited synergistic anticancer effects in TNBC cell lines, organoids, and patient-derived xenografts. This study demonstrates that, through inhibiting MAP2K4 methylation, CARM1i abrogates the feedback loop of MAP2K4 and PI3K signaling, supporting treatment with CARM1i as a therapeutic approach to improve the sensitivity of TNBC to PI3Ki. Significance: CARM1 mediates MAP2K4 activation and cross-talk with PI3K/AKT signaling, providing potential combination approaches for treating triple-negative breast cancer and explains the paradoxical role of MAP2K4 in ER+ and triple-negative breast cancer.

15 August 2025
Verified
Other
Open access
PDF file
EKEui-Jun Kim
Eui-Jun Kim
YWYidan Wang
Yidan Wang
YCYu-Lin Chen
Yu-Lin Chen
MMMin Ma
Min Ma
PLPeng Liu
Peng Liu
WXWei Xu
Wei Xu
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)

15 August 2025
Verified
Other
Open access
PDF file
EKEui-Jun Kim
Eui-Jun Kim
YWYidan Wang
Yidan Wang
YCYu-Lin Chen
Yu-Lin Chen
MMMin Ma
Min Ma
PLPeng Liu
Peng Liu
WXWei Xu
Wei Xu
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.

15 August 2025
Verified
Other
Open access
PDF file
EKEui-Jun Kim
Eui-Jun Kim
YWYidan Wang
Yidan Wang
YCYu-Lin Chen
Yu-Lin Chen
MMMin Ma
Min Ma
PLPeng Liu
Peng Liu
WXWei Xu
Wei Xu
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration